| Literature DB >> 34045976 |
Israel Pérez-Torres1, Verónica Guarner-Lans2, Elizabeth Soria-Castro1, Linaloe Manzano-Pech1, Adrián Palacios-Chavarría3,4, Rafael Ricardo Valdez-Vázquez3,4, Jose Guillermo Domínguez-Cherit5,6, Hector Herrera-Bello3,4, Humberto Castillejos-Suastegui3,4, Lidia Moreno-Castañeda3,4, Gabriela Alanís-Estrada3,4, Fabián Hernández3,4, Omar González-Marcos5,6, Ricardo Márquez-Velasco7, María Elena Soto4,7.
Abstract
The kidnapping of theEntities:
Keywords: COVID-19; NEFAs; SARS-CoV-2; fatty acids; phospholipids; pneumonia
Year: 2021 PMID: 34045976 PMCID: PMC8144632 DOI: 10.3389/fphys.2021.667024
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Demographic characteristic of COVID-19 patients at admission.
| Woman | 11 (26) |
| Men | 31 (74) |
| DM | 18 (43) |
| SAH | 19 (45) |
| Dyslipidemia | 16 (38) |
| COPD | 3 (7) |
| CD | 1 (2) |
| ECKD | 4 (10) |
| Deaths | 3 (7) |
| Laboratory at the admission | |
| Mean ± SE | |
| Age | 62 ± 13 |
| BMI (kg/m2) | 29 ± 4 |
| Temperature (°C) | 36.6 ± 0.46 |
| PaO2 | 79.4 ± 38.4 |
| PCO2 | 33.1 ± 7.8 |
| PaO2/FiO2 | 123 ± 58.2 |
| SpO2/FiO2 | 123.6 ± 52 |
| HR | 77 ± 20 |
| MAP (mmHg) | 79 ± 11 |
| Glucose (70–105 mg/dL) | 160.1 ± 77 |
| Urea | 56.8 ± 53 |
| Ureic nitrogen | 25.5 ± 22.8 |
| Total cholesterol (mg/dL) | 138.3 ± 38.4 |
| Triglycerides (mg/dL) | 155.2 ± 81.7 |
| HDL (mg/dL) | 33.1 ± 8.3 |
| LDL (mg/dL) | 75.7 ± 30.1 |
| LDH (UI/L) | 314.7 ± 100.2 |
| TB | 0.66 ± 0.20 |
| BD | 0.22 ± 0.09 |
| Leukocytes (3.56–10.3 × 103/μL) | 11.4 ± 4.8 |
| Lymphocytes (0.99–3.24 × 103/μL) | 0.67 ± 0.40 |
| Platelets (1,50,000–5,00,000 × 103/μL) | 243.07 ± 87 |
| Ferritin (11–307 ng/mL) | 836.80 ± 757 |
| Laboratory at the admission | |
| Median (min–max) | |
| CRP (1–3 mg/L) | 151 (32–384) |
| Index N/L | 13 (1–106) |
| IL-6 (pg/mL) | 117.04 (7.8–638.5) |
| D-Dimer (0–0.24 μg/mL) | 900 (210–34920) |
Age range and serum biochemical of the healthy subjects.
| Age | 54 (31–64) |
| CT (mg/dL) | 168.5 (107–190) |
| TG (mg/dL) | 152.5 (130.6–236.6) |
| HDL (mg/dL) | 37.3 (29.4–48.5) |
| LDL (mg/dL) | 89.3 (37–123.3) |
Total fatty acid compositions in the plasma from the healthy subjects and COVID-19 patients.
| C16:0 | 35.78 ± 0.60 | ||
| C16:1 | 5.07 ± 0.28 | ||
| C18:0 | 13.50 ± 0.38 | ||
| C18:1n-9 | 18.80 ± 0.73 | ||
| C18:2n-6 | 22.01 ± 0.51 | ||
| γ-C18:3n-6 | 0.23 ± 0.02 | ||
| α-C18:3n-6 | 0.35 ± 0.02 | 0.43 ± 0.03 | NS |
| C20:3n-6 | 0.60 ± 0.03 | ||
| C20:4n-6 | 2.47 ± 0.16 | ||
| C20:5n-3 | 0.70 ± 0.08 | ||
| C22:6n-3 | 0.20 ± 0.06 | 0.11 ± 0.03 | NS |
Total fatty acid composition of saturated, monounsaturated, and polyunsaturated in the plasma from the healthy subjects and COVID-19 patients.
| SFA | 49.10 ± 0.83 | ||
| MUFA | 23.82 ± 0.70 | ||
| PUFA (n-3) | 0.91 ± 0.11 | ||
| PUFA (n-6) | 25.94 ± 0.53 |
Indirect desaturation indexes of the desaturases in the total fatty acids from healthy subjects and COVID-19 patients.
| C16:1n-7/C16:0 (Δ9) | 0.14 ± 0.007 | ||
| C18:1n-9/C18:0 (Δ9) | 1.43 ± 0.08 | ||
| γ-C18:3n-6/C18:2n-6 (Δ6) | 0.010 ± 0.001 | ||
| C20:4n-6/C20:3n-6 (Δ5) | 4.88 ± 0.62 | ||
| C22:6n-3/C20:5n-3 (Δ5) | 0.26 ± 0.06 | 0.33 ± 0.05 | NS |
FIGURE 1Total phospholipids in plasma of HS and COVID-19 patients. The main phospholipids are phosphatidylserine, phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, and phosphatidylinositol. A decrease significant is observed in COVID-19 patients vs. HS. Statistical significance was determined by the Mann–Whitney rank sum test followed by the normality test (Shapiro-Wilk). Values expressed represent the median and Min–Max range (n = 42 COVID-19 patients and 22 HS). COVID-19 = coronavirus disease-19, HS = healthy subjects.
Fatty acid compositions of the phospholipids in plasma from the healthy subjects and COVID-19 patients.
| C16:0 | 26.34 ± 0.62 | ||
| C16:1 | 3.20 ± 0.31 | 2.78 ± 0.26 | NS |
| C18:0 | 5.57 ± 0.21 | ||
| C18:1n-9 | 26.81 ± 0.84 | ||
| C18:2n-6 | 33.18 ± 0.89 | ||
| γ-C18:3n-6 | 0.31 ± 0.04 | ||
| α-C18:3n-6 | 0.48 ± 0.03 | 0.52 ± 0.07 | NS |
| C20:3n-6 | 1.40 ± 0.16 | ||
| C20:4n-6 | 2.61 ± 0.19 | 2.35 ± 0.13 | NS |
| C20:5n-3 | 0.03 ± 0.01 | 0.06 ± 0.02 | NS |
| C22:6n-3 | 0.01 ± 0.009 | 0.04 ± 0.01 | NS |
Fatty acid compositions of the phospholipids; saturated, monounsaturated, and polyunsaturated in the plasma from the healthy subjects and COVID-19 patients.
| SFA | 31.92 ± 0.58 | ||
| MUFA | 30.01 ± 0.91 | ||
| PUFA (n-3) | 0.04 ± 0.01 | 0.10 ± 0.02 | NS |
| PUFA (n-6) | 38.00 ± 1.04 |
Indirect desaturation indexes of the desaturases in the fatty acids of the phospholipids from healthy subjects and COVID-19 patients.
| C16:1n-7/C16:0 (Δ9) | 0.11 ± 0.01 | ||
| C18:1n-9/C18:0 (Δ9) | 4.91 ± 0.27 | ||
| γ-C18:3n-6/C18:2n-6 (Δ6) | 0.009 ± 0.001 | 0.01 ± 0.002 | NS |
| C20:4n-6/C20:3n-6 (Δ5) | 2.69 ± 0.61 | ||
| C22:6n-3/C20:5n-3 (Δ5) | 0.19 ± 0.19 | 0.39 ± 0.13 | NS |
FIGURE 2Total NEFAs in plasma of healthy subjects and COVID-19 patients. A decrease significant is observed in COVID-19 patients vs. HS. Statistical significance was determined by the Mann–Whitney rank sum test followed by the normality test (Shapiro-Wilk). Values expressed represent the median and Min–Max range (n = 42 COVID-19 patients and 22 HS). COVID-19 = coronavirus disease-19, HS = healthy subjects, NEFAS = non-esterified fatty acids.
Fatty acid compositions of the NEFAs in the plasma from the healthy subjects and COVID-19 patients.
| C16:0 | 34.20 ± 0.85 | 33.60 ± 0.86 | NS |
| C16:1 | 4.63 ± 0.94 | ||
| C18:0 | 14.55 ± 0.47 | ||
| C18:1n-9 | 21.11 ± 1.20 | ||
| C18:2n-6 | 15.61 ± 0.52 | ||
| γ-C18:3n-6 | 0.87 ± 0.16 | 0.73 ± 0.12 | NS |
| α-C18:3n-6 | 0.93 ± 0.22 | 0.79 ± 0.15 | NS |
| C20:3n-6 | 6.01 ± 0.75 | ||
| C20:4n-6 | 1.54 ± 0.11 | 1.43 ± 0.17 | NS |
| C20:5n-3 | 0.41 ± 0.11 | ||
| C22:6n-3 | 0.09 ± 0.046 |
Fatty acid compositions of the NEFAs; saturated, monounsaturated, and polyunsaturated in the plasma from the healthy subjects and COVID-19 patients.
| SFA | 48.75 ± 1.05 | ||
| MUFA | 25.74 ± 1.14 | 27.79 ± 1.07 | NS |
| PUFA (n-3) | 0.51 ± 0.12 | ||
| PUFA (n-6) | 24.98 ± 0.73 | 24.71 ± 0.85 | NS |
FIGURE 3The SARS-CoV-2 can modulate and rearrange the host lipid profile to reach an intricate homeostasis which is optimal for viral replication and propagation. However, any exogenous manipulation that disrupts this the equilibrium might interfere with the replication of the virus such as high EPA and DHA concentration that decrease pro-inflammatory state being precursor of SPMs to and probably the AA however this FA might have two effects; increase inflammatory and thrombotic prostaglandins that would aggravate the infection by SARS-CoV-2 and/or decrease viral replication and propagation. AA = arachidonic acid, ACE2 = angiotensin converting enzyme 2, COX = cyclooxygenase, CT = cholesterol, D-γ-LA = dihomo-γ-linolenic acid, DHA = docosahexaenoic acid, EPA = eicosapentaenoic acid, FA = Fatty Acid, GPx = glutathione peroxidase, GR = glutathione reductase, GSH = glutathione, GSSG = oxidized glutathione, H2O2 = hydrogen peroxide, LA = linoleic acid, LOX = lipoxygenase, O2 = superoxide anion, PGE2 = prostaglandin E2, PL = phospholipids, PLA2 = phospholipase A2, PUFA = polyunsaturated fatty acids, SOD = superoxide dismutase, SPMs = specialized pro-resolving mediators, TXA2 = thromboxane A2, γ-LA = γ-linoleic acid.